000285360 001__ 285360
000285360 005__ 20260226114927.0
000285360 0247_ $$2doi$$a10.1016/j.nicl.2026.103963
000285360 0247_ $$2pmid$$apmid:41690259
000285360 0247_ $$2pmc$$apmc:PMC12925280
000285360 037__ $$aDZNE-2026-00225
000285360 041__ $$aEnglish
000285360 082__ $$a610
000285360 1001_ $$aEckenweber, Sebastian$$b0
000285360 245__ $$aAdditive value of early-phase β-Amyloid-PET for the differential diagnosis of non-Alzheimer's disease dementia.
000285360 260__ $$a[Amsterdam u.a.]$$bElsevier$$c2026
000285360 3367_ $$2DRIVER$$aarticle
000285360 3367_ $$2DataCite$$aOutput Types/Journal article
000285360 3367_ $$0PUB:(DE-HGF)16$$2PUB:(DE-HGF)$$aJournal Article$$bjournal$$mjournal$$s1772102764_7492
000285360 3367_ $$2BibTeX$$aARTICLE
000285360 3367_ $$2ORCID$$aJOURNAL_ARTICLE
000285360 3367_ $$00$$2EndNote$$aJournal Article
000285360 520__ $$aRecent studies demonstrated strong agreement between early-phase β-amyloid-PET perfusion imaging and glucose hypometabolism assessed by [18F]FDG-PET, indicating the potential of early-phase β-amyloid-PET as a surrogate biomarker of neuronal injury. We therefore aimed to investigate the additive value of early-phase β-amyloid-PET for the differential diagnosis of non-Alzheimer's disease dementia syndromes in clinical routine.[18F]florbetaben- and [18F]flutemetamol-PET scans (n = 379) performed between July 2013 and July 2021 were analyzed for their amyloid status and the presence of a neurodegenerative hypoperfusion pattern using visual assessment and z-score maps. In patients visually rated as amyloid-negative/neurodegeneration-positive (A-N+), the most likely diagnosis based on perfusion patterns was compared to the final clinical diagnosis, i.e. frontotemporal dementia or psychiatric disorders, suspected 4R-tauopathy, and suspected non-Alzheimer pathophysiology. Logistic regression models based on a data-driven selection of cerebral regions of hypoperfusion by principal component analysis were used to predict neurodegenerative disease and clinical diagnoses. Diagnostic accuracy was compared between visual assessment and the regression models.Neurodegeneration status was correctly identified in 78.8% (119/151) of amyloid-negative patients through visual rating, compared to 67.5% (102/151) using logistic regression. Visual assessment assigned 75.3% (67/89) of A-N+ patients to the correct diagnostic category. In contrast, the regression model classified 69.7% (62/89) of patients.The current study demonstrates an additive value of early-phase β-amyloid-PET for the differential diagnosis of dementia syndromes. While visual assessment of early-phase β-amyloid-PET already provides substantial diagnostic accuracy, a data-driven analysis approach could aid in cases of uncertainty.
000285360 536__ $$0G:(DE-HGF)POF4-353$$a353 - Clinical and Health Care Research (POF4-353)$$cPOF4-353$$fPOF IV$$x0
000285360 536__ $$0G:(DE-HGF)POF4-352$$a352 - Disease Mechanisms (POF4-352)$$cPOF4-352$$fPOF IV$$x1
000285360 588__ $$aDataset connected to CrossRef, PubMed, , Journals: pub.dzne.de
000285360 650_7 $$2Other$$a4-repeattauopathy
000285360 650_7 $$2Other$$aData driven
000285360 650_7 $$2Other$$aEarly-phaseβ-amyloid-PET
000285360 650_7 $$2Other$$aFrontotemporal dementia
000285360 650_7 $$2Other$$aMultinomial logistic regression
000285360 650_7 $$2Other$$aSuspected non-Alzheimer pathophysiology
000285360 7001_ $$aVölter, Friederike$$b1
000285360 7001_ $$aFranzmeier, Nicolai$$b2
000285360 7001_ $$0P:(DE-2719)9000852$$aPalleis, Carla$$b3$$udzne
000285360 7001_ $$0P:(DE-2719)9001249$$aWagemann, Olivia$$b4$$udzne
000285360 7001_ $$0P:(DE-2719)9000882$$aWeidinger, Endy$$b5$$udzne
000285360 7001_ $$0P:(DE-2719)9001160$$aKatzdobler, Sabrina$$b6$$udzne
000285360 7001_ $$aWlasich, Elisabeth$$b7
000285360 7001_ $$aSandkühler, Katja$$b8
000285360 7001_ $$aBöning, Guido$$b9
000285360 7001_ $$0P:(DE-2719)9001652$$aGnoerich, Johannes$$b10$$udzne
000285360 7001_ $$0P:(DE-2719)9001444$$aScheifele, Maximilian$$b11
000285360 7001_ $$aEckenweber, Florian$$b12
000285360 7001_ $$0P:(DE-2719)9002557$$aJanowitz, Daniel$$b13$$udzne
000285360 7001_ $$0P:(DE-2719)9000176$$aKurz, Carolin$$b14
000285360 7001_ $$0P:(DE-2719)2812234$$aPerneczky, Robert$$b15$$udzne
000285360 7001_ $$0P:(DE-2719)2811351$$aBürger, Katharina$$b16$$udzne
000285360 7001_ $$0P:(DE-2719)2810712$$aDanek, Adrian$$b17$$udzne
000285360 7001_ $$0P:(DE-2719)2811373$$aHöglinger, Günter$$b18$$udzne
000285360 7001_ $$0P:(DE-2719)2811659$$aLevin, Johannes$$b19$$udzne
000285360 7001_ $$0P:(DE-2719)9001539$$aBrendel, Matthias$$b20$$udzne
000285360 7001_ $$aSchönecker, Sonja$$b21
000285360 773__ $$0PERI:(DE-600)2701571-3$$a10.1016/j.nicl.2026.103963$$gVol. 49, p. 103963 -$$p103963$$tNeuroImage: Clinical$$v49$$x2213-1582$$y2026
000285360 8564_ $$uhttps://pub.dzne.de/record/285360/files/DZNE-2026-00225.pdf$$yRestricted
000285360 8564_ $$uhttps://pub.dzne.de/record/285360/files/DZNE-2026-00225.pdf?subformat=pdfa$$xpdfa$$yRestricted
000285360 9101_ $$0I:(DE-588)1065079516$$6P:(DE-2719)9000852$$aDeutsches Zentrum für Neurodegenerative Erkrankungen$$b3$$kDZNE
000285360 9101_ $$0I:(DE-588)1065079516$$6P:(DE-2719)9001249$$aDeutsches Zentrum für Neurodegenerative Erkrankungen$$b4$$kDZNE
000285360 9101_ $$0I:(DE-588)1065079516$$6P:(DE-2719)9000882$$aDeutsches Zentrum für Neurodegenerative Erkrankungen$$b5$$kDZNE
000285360 9101_ $$0I:(DE-588)1065079516$$6P:(DE-2719)9001160$$aDeutsches Zentrum für Neurodegenerative Erkrankungen$$b6$$kDZNE
000285360 9101_ $$0I:(DE-HGF)0$$6P:(DE-2719)9001652$$aExternal Institute$$b10$$kExtern
000285360 9101_ $$0I:(DE-HGF)0$$6P:(DE-2719)9002557$$aExternal Institute$$b13$$kExtern
000285360 9101_ $$0I:(DE-588)1065079516$$6P:(DE-2719)9000176$$aDeutsches Zentrum für Neurodegenerative Erkrankungen$$b14$$kDZNE
000285360 9101_ $$0I:(DE-588)1065079516$$6P:(DE-2719)2812234$$aDeutsches Zentrum für Neurodegenerative Erkrankungen$$b15$$kDZNE
000285360 9101_ $$0I:(DE-HGF)0$$6P:(DE-2719)2811351$$aExternal Institute$$b16$$kExtern
000285360 9101_ $$0I:(DE-HGF)0$$6P:(DE-2719)2810712$$aExternal Institute$$b17$$kExtern
000285360 9101_ $$0I:(DE-588)1065079516$$6P:(DE-2719)2811373$$aDeutsches Zentrum für Neurodegenerative Erkrankungen$$b18$$kDZNE
000285360 9101_ $$0I:(DE-588)1065079516$$6P:(DE-2719)2811659$$aDeutsches Zentrum für Neurodegenerative Erkrankungen$$b19$$kDZNE
000285360 9101_ $$0I:(DE-588)1065079516$$6P:(DE-2719)9001539$$aDeutsches Zentrum für Neurodegenerative Erkrankungen$$b20$$kDZNE
000285360 9131_ $$0G:(DE-HGF)POF4-353$$1G:(DE-HGF)POF4-350$$2G:(DE-HGF)POF4-300$$3G:(DE-HGF)POF4$$4G:(DE-HGF)POF$$aDE-HGF$$bGesundheit$$lNeurodegenerative Diseases$$vClinical and Health Care Research$$x0
000285360 9131_ $$0G:(DE-HGF)POF4-352$$1G:(DE-HGF)POF4-350$$2G:(DE-HGF)POF4-300$$3G:(DE-HGF)POF4$$4G:(DE-HGF)POF$$aDE-HGF$$bGesundheit$$lNeurodegenerative Diseases$$vDisease Mechanisms$$x1
000285360 915__ $$0StatID:(DE-HGF)0100$$2StatID$$aJCR$$bNEUROIMAGE-CLIN : 2022$$d2025-11-12
000285360 915__ $$0StatID:(DE-HGF)0200$$2StatID$$aDBCoverage$$bSCOPUS$$d2025-11-12
000285360 915__ $$0StatID:(DE-HGF)0300$$2StatID$$aDBCoverage$$bMedline$$d2025-11-12
000285360 915__ $$0StatID:(DE-HGF)0320$$2StatID$$aDBCoverage$$bPubMed Central$$d2025-11-12
000285360 915__ $$0StatID:(DE-HGF)0501$$2StatID$$aDBCoverage$$bDOAJ Seal$$d2025-08-21T14:52:24Z
000285360 915__ $$0StatID:(DE-HGF)0500$$2StatID$$aDBCoverage$$bDOAJ$$d2025-08-21T14:52:24Z
000285360 915__ $$0StatID:(DE-HGF)0030$$2StatID$$aPeer Review$$bDOAJ : Anonymous peer review$$d2025-08-21T14:52:24Z
000285360 915__ $$0StatID:(DE-HGF)0199$$2StatID$$aDBCoverage$$bClarivate Analytics Master Journal List$$d2025-11-12
000285360 915__ $$0StatID:(DE-HGF)1110$$2StatID$$aDBCoverage$$bCurrent Contents - Clinical Medicine$$d2025-11-12
000285360 915__ $$0StatID:(DE-HGF)0160$$2StatID$$aDBCoverage$$bEssential Science Indicators$$d2025-11-12
000285360 915__ $$0StatID:(DE-HGF)0113$$2StatID$$aWoS$$bScience Citation Index Expanded$$d2025-11-12
000285360 915__ $$0StatID:(DE-HGF)0150$$2StatID$$aDBCoverage$$bWeb of Science Core Collection$$d2025-11-12
000285360 915__ $$0StatID:(DE-HGF)9900$$2StatID$$aIF < 5$$d2025-11-12
000285360 915__ $$0StatID:(DE-HGF)0561$$2StatID$$aArticle Processing Charges$$d2025-11-12
000285360 915__ $$0StatID:(DE-HGF)0700$$2StatID$$aFees$$d2025-11-12
000285360 9201_ $$0I:(DE-2719)1111015$$kClinical Research (Munich)$$lClinical Research (Munich)$$x0
000285360 9201_ $$0I:(DE-2719)5000022$$kAG Dichgans$$lVascular Cognitive Impairment & Post-Stroke Dementia$$x1
000285360 9201_ $$0I:(DE-2719)1111016$$kAG Levin$$lClinical Neurodegeneration$$x2
000285360 9201_ $$0I:(DE-2719)1110007$$kAG Haass$$lMolecular Neurodegeneration$$x3
000285360 980__ $$ajournal
000285360 980__ $$aEDITORS
000285360 980__ $$aVDBINPRINT
000285360 980__ $$aI:(DE-2719)1111015
000285360 980__ $$aI:(DE-2719)5000022
000285360 980__ $$aI:(DE-2719)1111016
000285360 980__ $$aI:(DE-2719)1110007
000285360 980__ $$aUNRESTRICTED